Number Needed To Treat As A Tool For Cost Effectiveness Analysis: A Case Study In Renal Transplantation

Simple item page
dc.contributor.authorGupta, P.en_US
dc.contributor.authorGamad, N.en_US
dc.contributor.authorMohan, P.en_US
dc.date.accessioned2020-09-24T08:01:49Z
dc.date.available2020-09-24T08:01:49Z
dc.date.issued2020-06
dc.description.abstractObjective: To assess the utility of number needed to treat (NNT) as a tool for cost effectiveness analysis. Methods: Two monoclonal antibodies (MAbs), used for induction therapy viz basiliximab and daclizumab in renal transplantation, were identified. Pivotal placebo controlled clinical trials, mentioned in the innovator package inserts, were compared and analyzed for acute graft rejection and graft survival at 12 mo. NNT viz-a-vis cost was calculated and compared. Results: Daclizumab was comparable to basiliximab for acute graft rejection (NNT 10 vs. 9) but better for graft survival (20 vs. 25) at 12 mo, when used along with triple drug regimen (cyclosporine, azathioprine and corticosteroid). However, considering the cost of regimen for these drugs, in terms of NNT, basiliximab was more cost effective (INR 12,52,044 vs. 28,70,400 for acute rejection and INR 34,77,900 vs. 57,40,800 for graft survival). On the other hand, when these MAbs were used along with dual drug regimen (cyclosporine and corticosteroid), daclizumab was more cost effective for graft survival at 12 mo. The higher cost of daclizumab regimen (INR 2,87,040 vs. 1,39,116 for basiliximab) was offset by its substantially lower NNT (20 vs. 58-75 for one extra graft survival at 12 mo). Conclusion: This study demonstrates the utility of NNT in ascertaining relative effectiveness of treatment modalities that would help to formulate appropriate healthcare policies.en_US
dc.identifier.affiliationsPharmacology, All India Institute of Medical Sciences, New Delhien_US
dc.identifier.affiliationsSenior Resident, Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarhen_US
dc.identifier.affiliationsPharmacology, Armed Forces Medical College, Puneen_US
dc.identifier.citationGupta P., Gamad N., Mohan P.. Number Needed To Treat As A Tool For Cost Effectiveness Analysis: A Case Study In Renal Transplantation. International Journal of Pharmacy and Pharmaceutical Sciences. 2020 Jun; 12(6): 72-75en_US
dc.identifier.issn0975-1491
dc.identifier.issn2656-0097
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/206112
dc.languageenen_US
dc.publisherInnovare Academic Sciences Pvt. Ltd.en_US
dc.relation.issuenumber6en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.22159/ijpps.2020v12i6.34578en_US
dc.subjectNumber need to treaten_US
dc.subjectCost effectiveness analysisen_US
dc.subjectRenal transplantationen_US
dc.subjectDaclizumaben_US
dc.subjectBasiliximaben_US
dc.subjectMonoclonal antibodiesen_US
dc.titleNumber Needed To Treat As A Tool For Cost Effectiveness Analysis: A Case Study In Renal Transplantationen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpps2020v12n6p76.pdf
Size:
204.51 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Pharmacy and Pharmaceutical Sciences